MedStar Authors catalog › Details for: A review of GLP-1 receptor agonists: Evolution and advancement, through the lens of randomised controlled trials. [Review]
A review of GLP-1 receptor agonists: Evolution and advancement, through the lens of randomised controlled trials. [Review] Journal: Diabetes, obesity & metabolism.Published: 2018ISSN: 1462-8902.UI/PMID: 29364586.Subject(s): Clinical Trials, Phase III as Topic | *Diabetes Mellitus/dt [Drug Therapy] | Glucagon-Like Peptide 1/aa [Analogs & Derivatives] | Glucagon-Like Peptide 1/tu [Therapeutic Use] | *Glucagon-Like Peptide-1 Receptor/ag [Agonists] | Glucagon-Like Peptides/aa [Analogs & Derivatives] | Glucagon-Like Peptides/tu [Therapeutic Use] | Humans | *Hypoglycemic Agents/tu [Therapeutic Use] | Immunoglobulin Fc Fragments/tu [Therapeutic Use] | Liraglutide/tu [Therapeutic Use] | Peptides/tu [Therapeutic Use] | Randomized Controlled Trials as Topic | Recombinant Fusion Proteins/tu [Therapeutic Use] | Treatment Outcome | Weight Loss/de [Drug Effects]Institution(s): MedStar Health Research InstituteActivity type: Journal Article.Medline article type(s): Journal Article | ReviewDigital Object Identifier: https://dx.doi.org/10.1111/dom.13162 (Click here) ORCID: Aroda, Vanita R https://orcid.org/0000-0002-7706-4585 (Click here) Abbreviated citation: Diabetes Obes Metab. 20 Suppl 1:22-33, 2018 02.Abstract: AIMS: To review the evolution and advancement of GLP-1 receptor agonist (GLP-1RA) therapy, through the lens of randomised controlled trials, from differentiating characteristics, efficacy, safety, tolerability, and cardiovascular outcomes, to evidence gaps and next steps.Abstract: METHODS: Clinical review of published phase 3 or later RCT data studying efficacy, safety, and outcomes of approved GLP-1 RA therapies.Abstract: RESULTS: Through a wealth of studies, including both placebo-controlled and active-controlled studies, GLP-1 RAs have demonstrated high glycemic efficacy and ability to facilitate weight loss, with minimal risk of hypoglycemia, potential to restore beta cell function, and evidence for improved cardiovascular outcomes in those at risk.Abstract: CONCLUSIONS: Over a decade of clinical studies have established the unique contributions of GLP-1 RAs in the treatment of diabetes. Individual differences between the different GLP-1 RAs, in delivery, pharmacokinetic and clinical effects, exist, allowing for tailored approaches to clinical care. The strength of evidence generated through RCTs, both short-term and long-term studies, will continue to evolve and inform our current paradigms in diabetes care.Abstract: Copyright (c) 2018 John Wiley & Sons Ltd.